Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy

doi:10.3748/wjg.v24.i6.725

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 24, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7518)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-6) series.

Item

Count

PDF

529

WORD

298

HTML

4025

Figures (1-4)

133

Tables (1-6)

109

Sum=5094

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1009

Download

1415

Sum=2424

Feb 14, 2018 (publication date) through Jul 16, 2024

Times Cited of This Article

Times Cited (9)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Feb 14, 2018; 24(6): 725-736
Published online Feb 14, 2018. doi: 10.3748/wjg.v24.i6.725

Full Size Figure Download Figure

Figure 4 Possible mechanisms for HBsAg decline after nucleos(t)ide analogue treatment. A: Nucleos(t)ide analogues inhibit the activity of HBV reverse transcriptase; B: The production of relaxed circular DNA; C and D: The package andrelease of complete virions, and the replenishment of cccDNA. cccDNA: Covalently closed circular DNA; HBc: Hepatitis B core protein; HBsAg: Hepatitis B surface antigen; L/M/S proteins: Large, middle, and small envelope proteins; HBV: Hepatitis B virus.

Citation: Lin TC, Chiu YC, Chiu HC, Liu WC, Cheng PN, Chen CY, Chang TT, Wu IC. Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy. World J Gastroenterol 2018; 24(6): 725-736
URL: https://www.wjgnet.com/1007-9327/full/v24/i6/725.htm
DOI: https://dx.doi.org/10.3748/wjg.v24.i6.725